Severe and steroid-resistant Crohn's disease

Details

Serval ID
serval:BIB_29863AEC070E
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Severe and steroid-resistant Crohn's disease
Journal
Digestion
Author(s)
Michetti  Pierre, Mottet  Christian, Juillerat  Pascal, Pittet  Valérie, Felley  Christian, Vader  John-Paul, Gonvers  Jean-Jacques, Froehlich  Florian
ISSN
0012-2823
Publication state
Published
Issued date
2007
Peer-reviewed
Oui
Volume
76
Number
2
Pages
99-108
Language
english
Notes
SAPHIRID:64239
Abstract
Patients with moderate-to-severe disease and patients with steroid-refractory or steroid-dependent disease differ in their management, as the latter two groups usually involve patients whose condition is less acute. Systemic corticosteroids represent the mainstay of the management of moderate-to-severe disease and remain the first-line therapy in this setting. Anti-TNF agents represent choice alternatives for patients who do not respond to steroids or in whom steroids are contraindicated. Purine analogues, methotrexate and infliximab have all shown efficacy in achieving steroid-free remission in patients with steroid-refractory or steroid-dependent disease. Other fast-acting immunosuppressors showed little benefit. Surgery may be indicated in this setting. Natalizumab may prove useful in patients refractory to infliximab and other anti-TNF agents. [Ed.]
Pubmed
Web of science
Create date
03/03/2008 10:52
Last modification date
20/08/2019 13:09
Usage data